Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ATOS's Cash to Debt is ranked higher than
99% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.05 vs. ATOS: No Debt )
ATOS' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: No Debt

Equity to Asset 0.92
ATOS's Equity to Asset is ranked higher than
97% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. ATOS: 0.92 )
ATOS' s 10-Year Equity to Asset Range
Min: -0.66   Max: 0.95
Current: 0.92

-0.66
0.95
Interest Coverage No Debt
ATOS's Interest Coverage is ranked higher than
80% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 127.94 vs. ATOS: No Debt )
ATOS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 21.44
M-Score: -6.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -7505.06
ATOS's Operating margin (%) is ranked lower than
57% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. ATOS: -7505.06 )
ATOS' s 10-Year Operating margin (%) Range
Min: -171450   Max: -1051.66
Current: -7505.06

-171450
-1051.66
Net-margin (%) -7506.33
ATOS's Net-margin (%) is ranked lower than
56% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.29 vs. ATOS: -7506.33 )
ATOS' s 10-Year Net-margin (%) Range
Min: -172100   Max: -1053.94
Current: -7506.33

-172100
-1053.94
ROE (%) -84.74
ATOS's ROE (%) is ranked higher than
50% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. ATOS: -84.74 )
ATOS' s 10-Year ROE (%) Range
Min: -972.32   Max: -136.71
Current: -84.74

-972.32
-136.71
ROA (%) -76.27
ATOS's ROA (%) is ranked lower than
53% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.28 vs. ATOS: -76.27 )
ATOS' s 10-Year ROA (%) Range
Min: -223   Max: -102.65
Current: -76.27

-223
-102.65
ROC (Joel Greenblatt) (%) -2706.07
ATOS's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.50 vs. ATOS: -2706.07 )
ATOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6678.02   Max: -1143
Current: -2706.07

-6678.02
-1143
» ATOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ATOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.30
ATOS's P/B is ranked higher than
76% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. ATOS: 3.30 )
ATOS' s 10-Year P/B Range
Min: 2.19   Max: 23.02
Current: 3.3

2.19
23.02
EV-to-EBIT -3.89
ATOS's EV-to-EBIT is ranked higher than
59% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 168.09 vs. ATOS: -3.89 )
ATOS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.89

Current Ratio 9.39
ATOS's Current Ratio is ranked higher than
94% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. ATOS: 9.39 )
ATOS' s 10-Year Current Ratio Range
Min: 0.01   Max: 16.36
Current: 9.39

0.01
16.36
Quick Ratio 9.39
ATOS's Quick Ratio is ranked higher than
94% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. ATOS: 9.39 )
ATOS' s 10-Year Quick Ratio Range
Min: 0.01   Max: 16.36
Current: 9.39

0.01
16.36

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.60
ATOS's Price/Net Cash is ranked higher than
95% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ATOS: 4.60 )
ATOS' s 10-Year Price/Net Cash Range
Min: 2.68   Max: 390
Current: 4.6

2.68
390
Price/Net Current Asset Value 4.60
ATOS's Price/Net Current Asset Value is ranked higher than
93% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ATOS: 4.60 )
ATOS' s 10-Year Price/Net Current Asset Value Range
Min: 2.64   Max: 390
Current: 4.6

2.64
390
Price/Tangible Book 4.30
ATOS's Price/Tangible Book is ranked higher than
77% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.22 vs. ATOS: 4.30 )
ATOS' s 10-Year Price/Tangible Book Range
Min: 2.45   Max: 97.5
Current: 4.3

2.45
97.5
Price/Median PS Value 1.00
ATOS's Price/Median PS Value is ranked lower than
54% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. ATOS: 1.00 )
ATOS' s 10-Year Price/Median PS Value Range
Min: 1.96   Max: 3.51
Current: 1

1.96
3.51

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:YAG.Germany
Atossa Genetics Inc. was incorporated in Delaware in April 2009. The company is a healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions. Its diagnostic tests consist of FDA-cleared and patented medical devices that can collect fluid and tissue samples from the breast milk ducts, where over 95% of breast cancers arise. These samples are processed at its CLIA-registered laboratory, the National Reference Laboratory for Breast Health, which screens the samples for the presence of normal, pre-malignant, or malignant changes as determined by cytopathology and biomarkers that distinguish "usual" ductal hyperplasia, a benign condition, from atypical ductal hyperplasia, which may lead to cancer. The company is currently offering two screening tests and plan to offer two additional tests by the end of 2012 or beginning of 2013. The tests that it currently offers and that are in development consists of the following: ForeCYTE: The ForeCYTE Breast Health Test, launched in December 2011, provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. It involves collecting a sample of nipple aspirate fluid, or NAF, using patented, FDA-cleared Mammary Aspirate Specimen Cytology Test, or MASCT, System, analyzing the NAF using a proprietary molecular and cellular biomarker test, and then processing the test results, together with the patient's medical and family history, through a clinically-validated risk assessment algorithm that calculates 10-year and lifetime risk of breast cancer; ArgusCYTE: The ArgusCYTE Breast Health Test, launched in December 2011, provides information to help inform breast cancer treatment options and to help monitor potential recurrence; FullCYTE: The FullCYTE Breast Health Test, which intends to launch in late 2012 or early 2013, is designed to assess the individual breast ducts for pre-cancerous changes in women previously identified to be at high risk for breast cancer: and NextCYTE: The NextCYTE Breast Cancer Test, which intends to launch in late 2012 or early 2013, is designed to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK